Indivior Pharmaceuticals (INDV) Amortization of Deferred Charges (2024 - 2026)

Indivior Pharmaceuticals' Amortization of Deferred Charges history runs 3 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges changed 0.0% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $10.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $10.0 million, down 16.67% from the prior year.
• Amortization of Deferred Charges fell to $2.0 million in Q1 2026 per INDV's latest filing, from $3.0 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $4.0 million in Q3 2024 and bottomed at $2.0 million in Q1 2025.
• The 3-year median for Amortization of Deferred Charges is $3.0 million (2025), against an average of $2.9 million.
• Across the five-year window, Amortization of Deferred Charges sank 50.0% in 2025 and changed 0.0% in 2026, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $4.0 million in 2024, then decreased by 25.0% to $3.0 million in 2025, then tumbled by 33.33% to $2.0 million in 2026.
• Per Business Quant, the three latest INDV Amortization of Deferred Charges figures stand at $2.0 million (Q1 2026), $3.0 million (Q4 2025), and $2.0 million (Q3 2025).